China Proton Therapy Market Industry Trends and Forecast to 2034: Segmented by (Product, System, Cancer, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034
Overview
Market Dashboard
China · 2024–2034 · placeholder estimates
Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the
full report.
Estimate 2024$105.9 MnPlaceholder estimate
Estimate 2025$117.0 Mn8.2% of the global market
Projected 2034$287.3 Mn 145.6%Adds $170.3 Mn over 9 forecast years
CAGR 2025–203410.5%Faster than 53% of 173 Medical Devices markets here
Key players5
China is 8.2% of the global market.
In APAC, the largest is China (this report) at $117.0 Mn.
29 in ChinaSource: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in China. Retrieved 12 Nov 2026.
Formats
PDF, PPTX, XLSX
Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.
The China Proton Therapy Market Analysis Executive Summary
Proton therapy is a type of radiation therapy that uses protons to target tumours more precisely and spare healthy tissue.
Key segments of the proton Therapy market include product (Proton Therapy Systems and Services), system (Single-Room Systems and Multi-Room Systems) and cancer (Pediatric Cancers, Brain and CNS and Head and Neck).
China Proton Therapy market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.
China Proton Therapy Market Dynamics
Market Growth Drivers
Rising cancer cases, earlier detection, precision medicine and a strong pipeline of targeted and immune therapies are driving the proton Therapy market. Faster approvals and new combinations are improving survival.
Opportunity
Biomarker-led treatment, earlier lines of therapy and expansion into emerging markets offer strong growth for the proton Therapy market.
Market Restraints
High treatment costs, drug resistance, side effects and unequal access to cancer centres hold back the proton Therapy market, especially in low- and middle-income countries.
Competitive Landscape for Proton Therapy Market in China
The proton Therapy market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.
Healthcare Policies and Regulatory Landscape for Proton Therapy Market in China
Proton Therapy in China: rules, payment and research
Medical devices are regulated by the National Medical Products Administration (NMPA) and its provincial offices: class I devices are filed, and class II and III devices are registered.[1] Basic medical insurance covers most people; the National Healthcare Security Administration (NHSA) runs it and sets the National Reimbursement Drug List.[2] ClinicalTrials.gov lists 29 studies on Proton Therapy that are recruiting, active or about to start in China.[3]
[3]ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in China. Retrieved 12 Nov 2026.
Policy changes and Reimbursement scenario
Medical device rules, such as the US FDA 510(k) and PMA pathways and the EU Medical Device Regulation, govern how proton Therapy products are approved and monitored. Reimbursement codes and hospital purchasing policies decide how widely they are used in China.
2.2 Market Size, Growth Prospects and Key findings
3 Market Dynamics
3.1 Market Growth Drivers Analysis
3.2 Market Restraints Analysis
4 Market Segmentation
4.1 By Product
4.2 By System
4.3 By Cancer
4.4 By End User
5 By Market Share
5.1 Market Analysis, Insights and Forecast – By Revenue
6 Competitive Landscape
6.1 Major Top Market Players Products in Pipeline
6.2 R&D Initiatives
6.3 Notable recent Deals
6.3.1 Strategic Divestments
6.3.2 Mergers & Acquisitions
6.3.3 Partnerships
6.3.4 Joint Ventures
7 Key Company Profiles
7.1 IBA (Ion Beam Applications)
7.2 Varian (Siemens Healthineers)
7.3 Hitachi
7.4 Mevion Medical Systems
7.5 Sumitomo Heavy Industries
8 Healthcare Policies and Regulatory Landscape
8.1 Policy changes and Reimbursement scenario
8.2 Government Initiatives / Intervention programs
The proton Therapy market can be segmented based on various criteria, including product, system, cancer and end user. Here's a breakdown of the market segmentation
Other companies that free public records show in this market: trials they lead, US approvals and WHO prequalification. They are not part of our key players research. Each count opens its source.
Also active in this area, from free public records
Source: ClinicalTrials.gov, Active studies (recruiting, about to start or running) each company leads, found with this market's trial search, worldwide. Retrieved 13 Nov 2026.
Source: FDA 510(k) and PMA databases, 510(k) clearances and PMA approvals since 2015 for devices whose name has this market's words. Retrieved 13 Nov 2026.
Beyond the market numbers
Research, trials and patients
What doctors and scientists are doing in Proton Therapy right now, from free public sources.
Sources:PubMed (US National Library of Medicine),
ClinicalTrials.gov,
World Bank.
Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.
Public data, with sources
Proton Therapy in context
China compared
Health spending per person: 763 US$ per person (2023). World: 1,317 US$ per person (2023). 5th highest of the 15 countries we cover in APAC.[1]
Doctors: 3.11 per 1,000 people (2022). World: 1.86 per 1,000 people (2022). 3rd highest of the 15 countries we cover in APAC.[2]
People aged 65 and over: 14.9% of people (2025). World: 10.4% of people (2025). 6th highest of the 16 countries we cover in APAC.[3]
[1]World Bank Open Data, Health spending per person (US$ per person). Retrieved 14 Nov 2026.
Placeholder estimate: about $117.0 Mn in 2025, rising to about $287.3 Mn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Proton Therapy market in China growing?
Placeholder estimate: about 10.5% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Proton Therapy market report cover?
The report splits the market by product (Proton Therapy Systems, Services), system (Single-Room Systems, Multi-Room Systems), cancer (Pediatric Cancers, Brain and CNS, Head and Neck, Prostate) and end user (Hospitals, Ambulatory Surgical Centers, Diagnostic Centers, Home Care Settings).
Who are the key players in the Proton Therapy market?
Key players include IBA (Ion Beam Applications), Varian (Siemens Healthineers), Hitachi Medical Systems, Mevion Medical Systems and Sumitomo Heavy Industries.
What is driving the Proton Therapy market?
Rising cancer cases, earlier detection, precision medicine and a strong pipeline of targeted and immune therapies are driving the proton Therapy market. Faster approvals and new combinations are improving survival.
Who regulates Proton Therapy in China?
Medical devices are regulated by the National Medical Products Administration (NMPA) and its provincial offices: class I devices are filed, and class II and III devices are registered. Source: National Medical Products Administration. Checked 14 Nov 2026.
How is healthcare paid for in China?
Basic medical insurance covers most people; the National Healthcare Security Administration (NHSA) runs it and sets the National Reimbursement Drug List. Source: National Healthcare Security Administration. Checked 14 Nov 2026.
How many clinical trials on Proton Therapy are running in China?
29 studies are recruiting, active or about to start in China, according to ClinicalTrials.gov. Source: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in China. Retrieved 12 Nov 2026.
How much research is published on Proton Therapy?
PubMed lists 3,474 papers on Proton Therapy added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.
China 
India
US
Canada
Japan
Germany
Brazil
UK
France
Ecuador
Italy
Spain
Saudi Arabia
Mexico
Australia
Russia
New Zealand
South Africa
UAE
Egypt
Philippines
Malaysia
Hong Kong
Singapore
Thailand
Kenya